Development and technology transfer of Haemophilus influenzae type b conjugate vaccines for developing countries
Authors:
- Michel BeurretMBMichel Beurret
- Ahd HamidiAHAhd Hamidi
- Hans KreeftenbergHKHans Kreeftenberg
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- The immunogenicity and safety of a reduced PRP-content DTPw-HBV/Hib vaccine when administered according to the accelerated EPI scheduleBMC Infectious Diseases, 2010
- The role of emerging manufacturers in access to innovative vaccines of public health importanceVaccine, 2010
- The Developing Countries Vaccine Manufacturers’ Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countriesVaccine, 2008
- Technology transfer of Sabin-IPV to new developing country marketsBiologicals, 2006
- An NMR Spectroscopic Identity Test for the Control of the Capsular Polysaccharide from Haemophilus influenzae Type bBiologicals, 2000
- Haemophilus influenzae type b conjugate vaccine stability: catalytic depolymerization of PRP in the presence of aluminum hydroxideVaccine, 1999
- A Simple and Rapid Method for Measuring Unconjugated Capsular Polysaccharide (PRP) ofHaemophilus influenzaetype b in PRP-tetanus toxoid conjugate vaccineBiologicals, 1998
- IMMUNOGENICITY IN INFANTS OF HAEMOPHILUS INFLUENZAE TYPE B POLYSACCHARIDE IN A CONJUGATE VACCINE WITH NEISSERIA MENINGITIDIS OUTER-MEMBRANE PROTEINThe Lancet, 1986
- Immunization of 2-month-old infants with protein-coupled oligosaccharides derived from the capsule of Haemophilus influenzae type bThe Journal of Pediatrics, 1985
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976